TW202325738A - 抗ctla-4抗體給藥方案 - Google Patents

抗ctla-4抗體給藥方案 Download PDF

Info

Publication number
TW202325738A
TW202325738A TW111141150A TW111141150A TW202325738A TW 202325738 A TW202325738 A TW 202325738A TW 111141150 A TW111141150 A TW 111141150A TW 111141150 A TW111141150 A TW 111141150A TW 202325738 A TW202325738 A TW 202325738A
Authority
TW
Taiwan
Prior art keywords
ctla
cancer
antibody
seq
dose
Prior art date
Application number
TW111141150A
Other languages
English (en)
Chinese (zh)
Inventor
陽 劉
盼 鄭
馬汀 戴芬波特
Original Assignee
美商昂科C4公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商昂科C4公司 filed Critical 美商昂科C4公司
Publication of TW202325738A publication Critical patent/TW202325738A/zh

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
TW111141150A 2021-10-29 2022-10-28 抗ctla-4抗體給藥方案 TW202325738A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163273660P 2021-10-29 2021-10-29
US63/273,660 2021-10-29

Publications (1)

Publication Number Publication Date
TW202325738A true TW202325738A (zh) 2023-07-01

Family

ID=86158833

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111141150A TW202325738A (zh) 2021-10-29 2022-10-28 抗ctla-4抗體給藥方案

Country Status (10)

Country Link
US (1) US20260139052A1 (cg-RX-API-DMAC7.html)
EP (1) EP4422685A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024540152A (cg-RX-API-DMAC7.html)
KR (1) KR20240099187A (cg-RX-API-DMAC7.html)
CN (1) CN118176021A (cg-RX-API-DMAC7.html)
AU (1) AU2022377644A1 (cg-RX-API-DMAC7.html)
CA (1) CA3234351A1 (cg-RX-API-DMAC7.html)
MX (1) MX2024004429A (cg-RX-API-DMAC7.html)
TW (1) TW202325738A (cg-RX-API-DMAC7.html)
WO (1) WO2023077069A1 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024238912A1 (en) * 2023-05-17 2024-11-21 OncoC4, Inc. Ph-sensitive anti-ctla-4 antibodies and uses thereof
WO2026041780A2 (en) * 2024-08-23 2026-02-26 BioNTech SE Combination therapy comprising anti-ctla4 antibodies and chemotherapy for cancer treatment

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ568016A (en) * 2005-12-07 2011-12-22 Medarex Inc CTLA-4 antibody dosage escalation regimens
EP2912063A1 (en) * 2012-10-23 2015-09-02 Bristol-Myers Squibb Company Combination of anti-kir and anti-ctla-4 antibodies to treat cancer
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
AU2016370648B2 (en) 2015-12-15 2023-03-09 OncoC4, Inc. Chimeric and humanized anti-human CTLA4 monoclonal antibodies and uses thereof
TWI799432B (zh) * 2017-07-27 2023-04-21 美商再生元醫藥公司 抗ctla-4抗體及其用途
CN119792515A (zh) * 2018-02-13 2025-04-11 默沙东有限责任公司 用抗pd-1抗体和抗ctla-4抗体治疗癌症的方法

Also Published As

Publication number Publication date
JP2024540152A (ja) 2024-10-31
EP4422685A1 (en) 2024-09-04
WO2023077069A1 (en) 2023-05-04
AU2022377644A1 (en) 2024-05-16
US20260139052A1 (en) 2026-05-21
EP4422685A4 (en) 2025-12-03
KR20240099187A (ko) 2024-06-28
CN118176021A (zh) 2024-06-11
CA3234351A1 (en) 2023-05-04
MX2024004429A (es) 2024-05-06

Similar Documents

Publication Publication Date Title
JP7519477B2 (ja) 非小細胞肺がんを治療するための抗b7-h1および抗ctla-4抗体
KR102661249B1 (ko) 종양 치료용 항-b7-h1 항체
TW202604568A (zh) 使用抗pd-1抗體與抗ctla-4抗體之組合以治療肺癌
CN110882385A (zh) 抗pd-1抗体在治疗肿瘤中的用途
US20260092112A1 (en) Use of anti-ctla-4 antibodies for treating adenoid cystic carcinoma
TW202342096A (zh) 靶向dll3的癌症治療
US20260139052A1 (en) Anti-ctla-4 antibody dosing regimens
JP2025504278A (ja) 抗pd1抗体の皮下投与により癌を治療するための組成物及び方法
JP2023011902A (ja) Pd-1阻害剤を投与することにより子宮頸がんを処置する方法
JP2021501150A (ja) 肝臓がんを治療するための組成物及び方法
WO2022223006A1 (zh) 抗pd-1抗体联合一线化疗治疗晚期非小细胞肺癌的用途
JP2024513247A (ja) 抗pd-1抗体の皮下投与によるがんの治療方法
CN117479955A (zh) 允许免疫细胞浸润到肿瘤中的方法
JP2024534080A (ja) 誘導性il-2及びpd-1/pd-l1の併用療法
HK40106641A (en) Anti-ctla-4 antibody dosing regimens
WO2019070497A1 (en) POLY THERAPY AGAINST CANCER
WO2025185682A1 (zh) 含有抗egfr抗体或其片段的联合用药物
TW202612729A (zh) 涉及抗hla-g抗體及抗egfr抗體以及抗pd-1抗體之組合療法
TW202517679A (zh) 以抗ilt2抗體治療癌症
JP2025524957A (ja) 抗GARP-TGF-β1/PD-1併用療法
HK40112915A (en) Anti-galectin-9 antibodies and therapeutic uses thereof
HK40121853A (en) Treatment of hematological malignancies with antibodies inhibiting galectin-9
HK1224560B (en) Anti-b7-h1 antibodies for treating tumors